Biohaven climbs as FDA says no advisory committee needed for genetic disorder drug

Biohaven

22/08/2025 12:50

** Shares of drugmaker Biohaven BHVN.N rise 9.2% to $16.03 premarket

** The U.S. FDA has told Biohaven that an advisory committee meeting originally planned for the application is no longer needed for decision-making, filing shows

** In May, the FDA extended the review period of the marketing application for its genetic disorder drug, troriluzole

** The health regulator's decision is still expected in Q4 of 2025

** Co is testing troriluzole for the treatment of adult patients with spinocerebellar ataxia, a rare disorder that affects movement and balance, and has no FDA-approved treatments

** Stock down 60% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))